Muscle histone deacetylase 4 upregulation in amyotrophic lateral sclerosis: Potential role in reinnervation ability and disease progression

Brain

Volumn 136, Issue 8, 2013, Pages 2359-2368

  Bruneteau, Gaëlle ^a,b,c   Simonet, Thomas ^d   Bauché, Stéphanie ^b,c,e   Mandjee, Nathalie ^b,c   Malfatti, Edoardo ^a   Girard, Emmanuelle ^d   Tanguy, Marie Laure ^a   Behin, Anthony ^a   Khiami, Frédéric ^a   Sariali, Elhadi ^a   Hell Remy, Caroline ^a   Salachas, François ^a   Pradat, Pierre François ^a   Fournier, Emmanuel ^a,b   Lacomblez, Lucette ^a   Koenig, Jeanine ^b,c   Romero, Norma Beatriz ^a   Fontaine, Bertrand ^b,c   Meininger, Vincent ^a   Schaeffer, Laurent ^d   Hantaï, Daniel ^a,b,c   more..

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d UNIVERSITÉ DE LYON   (France)

^e PSL RESEARCH UNIVERSITY   (France)

Author keywords

ALS; HDAC; Motor neuron; Neuromuscular junction; Reinnervation

Indexed keywords

HISTONE DEACETYLASE 4; MICRORNA; RILUZOLE; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; DISEASE COURSE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; MUSCLE ATROPHY; MUSCLE FUNCTION; MUSCLE REINNERVATION; NEUROMUSCULAR SYNAPSE; PARALYSIS; PRIORITY JOURNAL; RESPIRATORY FAILURE; SURVIVAL TIME; UPREGULATION;

EID: 84880960483     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awt164     Document Type: Article

References (32)

1. Ben Ammar A, Soltanzadeh P, Bauché S, Richard P, Goillot E, Herbst R, et al. A mutation causes MuSK reduced sensitivity to agrin and congenital myasthenia. PLoS One 2013; 8: e53826.
2. Bromberg MB, Forshew DA, Nau KL, Bromberg J, Simmons Z, Fries TJ. Motor unit number estimation, isometric strength, and electromyographic measures in amyotrophic lateral sclerosis. Muscle Nerve 1993; 16: 1213-9.
3. Brooke MH, Kaiser KK. Some comments on the histochemical characterization of muscle adenosine triphosphatase. J Histochem Cytochem 1969; 17: 431-2.
4. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 293-9.
5. Charcot JM, Joffroy A. Deux cas d'atrophie musculaire progressive avec lésions de la substance grise et des faisceaux antéro- latéraux de la moelle épinière. Arch Physiol Neurol Pathol 1869; 2: 744-60.
6. Cöers C. Morphologie de la jonction neuromusculaire. Arch Biol (Liège) 1964; 75: 905-41.
7. Cohen TJ, Barrientos T, Hartman ZC, Garvey SM, Cox GA, Yao TP. The deacetylase HDAC4 controls myocyte enhancing factor-2-dependent structural gene expression in response to neural activity. FASEB J 2009; 23: 99-106.
8. Cohen TJ, Waddell DS, Barrientos T, Lu Z, Feng G, Cox GA, et al. The histone deacetylase HDAC4 connects neural activity to muscle transcriptional reprogramming. J Biol Chem 2007; 282: 33752-9.
9. Donahue SP, Wood JG, English AW. On the role of the 200-kDa neurofilament protein at the developing neuromuscular junction. Dev Biol 1988; 130: 154-66.
10. Frey D, Schneider C, Xu L, Borg J, Spooren W, Caroni P. Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. J Neurosci 2000; 20: 2534-42.
11. Gattenlohner S, Schneider C, Thamer C, Klein R, Roggendorf W, Gohlke F, et al. Expression of foetal type acetylcholine receptor is restricted to type 1 muscle fibres in human neuromuscular disorders. Brain 2002; 125: 1309-19.
12. Hansen S, Ballantyne JP. A quantitative electrophysiological study of motor neurone disease. J Neurol Neurosurg Psychiatry 1978; 41: 773-83.
13. Huzé C, Bauche S, Richard P, Chevessier F, Goillot E, Gaudon K, et al. Identification of an agrin mutation that causes congenital myasthenia and affects synapse function. Am J Hum Genet 2009; 85: 155-67.
14. Johnson MA, Polgar J, Weightman D, Appleton D. Data on the distribution of fibre types in thirty-six human muscles. An autopsy study. J Neurol Sci 1973; 18: 111-29.
15. Koelle GB, Friedenwald JA. A histochemical method for localizing cholinesterase activity. Proc Soc Exp Biol Med 1949; 70: 617-22.
16. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996; 347: 1425-31.
17. Le Bozec S, Maton B. Differences between motor unit firing rate, twitch characteristics and fibre type composition in an agonistic muscle group in man. Eur J Appl Physiol Occup Physiol 1987; 56: 350-5.
18. Maselli RA, Mass DP, Distad BJ, Richman DP. Anconeus muscle: a human muscle preparation suitable for in-vitro microelectrode studies. Muscle Nerve 1991; 14: 1189-92.
19. Maselli RA, Wollman RL, Leung C, Distad B, Palombi S, Richman DP, et al. Neuromuscular transmission in amyotrophic lateral sclerosis. Muscle Nerve 1993; 16: 1193-203.
20. Mateen FJ, Carone M, Sorenson EJ. Patients who survive 5 years or more with ALS in Olmsted County, 1925-2004. J Neurol Neurosurg Psychiatry 2010; 81: 1144-6.
21. McComas AJ, Galea V, de Bruin H. Motor unit populations in healthy and diseased muscles. Phys Ther 1993; 73: 868-77.
22. Nelson LM. Epidemiology of ALS. Clin Neurosci 1995; 3: 327-31.
23. Pradat PF, Dubourg O, de Tapia M, di Scala F, Dupuis L, Lenglet T, et al. Muscle gene expression is a marker of amyotrophic lateral sclerosis severity. Neurodegener Dis 2012; 9: 38-52.
24. Pun S, Santos AF, Saxena S, Xu L, Caroni P. Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat Neurosci 2006; 9: 408-19.
25. Saltin B, Gollnick PD. Skeletal muscle adaptability: significance for metabolism and performance. In: Peachey LD, Adrian RH, Geiger SR, editors. Handbook of physiology. Bethesda: American Physiological Society; 1983. p. 555-631.
26. Schaefer AM, Sanes JR, Lichtman JW. A compensatory subpopulation of motor neurons in a mouse model of amyotrophic lateral sclerosis. J Comp Neurol 2005; 490: 209-19.
27. Turner MR, Parton MJ, Shaw CE, Leigh PN, Al Chalabi A. Prolonged survival in motor neuron disease: a descriptive study of the King's database 1990-2002. J Neurol Neurosurg Psychiatry 2003; 74: 995-7.
28. van Rooij E, Olson EN. MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 2007; 117: 2369-76.
29. Weber M, Neuwirth C, Thierbach J, Schweikert K, Czaplinski A, Petersen J, et al. ALS patients with SOD1 mutations in Switzerland show very diverse phenotypes and extremely long survival. J Neurol Neurosurg Psychiatry 2012; 83: 351-3.
30. Williams AH, Valdez G, Moresi V, Qi X, McAnally J, Elliott JL, et al. MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science 2009; 326: 1549-54.
31. Yoo YE, Ko CP. Treatment with trichostatin A initiated after disease onset delays disease progression and increases survival in a mouse model of amyotrophic lateral sclerosis. Exp Neurol 2011; 231: 147-59.
32. Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Samarelli V, et al. Predictors of long survival in amyotrophic lateral sclerosis: a population-based study. J Neurol Sci 2008; 268: 28-32.